De Groot, Anne S.
EpiVax Incorporated,
United States
2025 Rank: 78022
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 597 out of 75944 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 78022 | 64305 |
| Total Cites | 5239 | 7005 |
| H-index | 36 | 43 |
| Hm-index | 17 | 19 |
| Number of Single Authored Papers | 13 | 13 |
| Total Cites to Single Authored Papers | 207 | 227 |
| Number of Single+First Authored Papers | 78 | 78 |
| Total Cites to Single+First Authored Papers | 2479 | 3136 |
| Number of Single+First+Last Authored Papers | 178 | 178 |
| Total Cites to Single+First+Last Authored Papers | 4223 | 5547 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3897 | 4236 |
| Ratio of Total Citations to Distinct Citing Papers | 1.34 | 1.65 |
| Self-Citation Percentage |
25.21%
|
|
De Groot, Anne S.
EpiVax Incorporated,
United States
2024 Rank: 78368
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 620 out of 71672 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 78368 | 64241 |
| Total Cites | 4828 | 6500 |
| H-index | 34 | 42 |
| Hm-index | 16 | 19 |
| Number of Single Authored Papers | 13 | 13 |
| Total Cites to Single Authored Papers | 201 | 221 |
| Number of Single+First Authored Papers | 78 | 78 |
| Total Cites to Single+First Authored Papers | 2348 | 2973 |
| Number of Single+First+Last Authored Papers | 173 | 173 |
| Total Cites to Single+First+Last Authored Papers | 3924 | 5175 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3590 | 3916 |
| Ratio of Total Citations to Distinct Citing Papers | 1.34 | 1.66 |
| Self-Citation Percentage |
25.72%
|
|
De Groot, Anne S.
EpiVax Incorporated,
United States
2023 Rank: 77269
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 614 out of 68279 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 77269 | 62592 |
| Total Cites | 4514 | 6042 |
| H-index | 33 | 41 |
| Hm-index | 15 | 18 |
| Number of Single Authored Papers | 13 | 13 |
| Total Cites to Single Authored Papers | 197 | 217 |
| Number of Single+First Authored Papers | 76 | 76 |
| Total Cites to Single+First Authored Papers | 2243 | 2835 |
| Number of Single+First+Last Authored Papers | 168 | 168 |
| Total Cites to Single+First+Last Authored Papers | 3700 | 4862 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3328 | 3637 |
| Ratio of Total Citations to Distinct Citing Papers | 1.36 | 1.66 |
| Self-Citation Percentage |
25.29%
|
|
De Groot, Anne S.
EpiVax Incorporated,
United States
2022 Rank: 78161
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 652 out of 65731 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 78161 | 64804 |
| Total Cites | 4088 | 5551 |
| H-index | 31 | 39 |
| Hm-index | 14 | 16 |
| Number of Single Authored Papers | 12 | 12 |
| Total Cites to Single Authored Papers | 188 | 208 |
| Number of Single+First Authored Papers | 75 | 75 |
| Total Cites to Single+First Authored Papers | 2100 | 2679 |
| Number of Single+First+Last Authored Papers | 160 | 160 |
| Total Cites to Single+First+Last Authored Papers | 3386 | 4517 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3010 | 3305 |
| Ratio of Total Citations to Distinct Citing Papers | 1.36 | 1.68 |
| Self-Citation Percentage |
26.36%
|
|
De Groot, Anne S.
EpiVax Incorporated,
United States
2021 Rank: 76909
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 646 out of 64670 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 76909 | 62716 |
| Total Cites | 3920 | 5348 |
| H-index | 30 | 39 |
| Hm-index | 14 | 16 |
| Number of Single Authored Papers | 12 | 12 |
| Total Cites to Single Authored Papers | 180 | 199 |
| Number of Single+First Authored Papers | 73 | 73 |
| Total Cites to Single+First Authored Papers | 2037 | 2602 |
| Number of Single+First+Last Authored Papers | 155 | 155 |
| Total Cites to Single+First+Last Authored Papers | 3268 | 4374 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 2868 | 3157 |
| Ratio of Total Citations to Distinct Citing Papers | 1.37 | 1.69 |
| Self-Citation Percentage |
26.70%
|
|
De Groot, Anne S.
EpiVax Incorporated,
United States
2020 Rank: 74045
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 692 out of 58416 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 74045 | 59913 |
| Total Cites | 3513 | 4805 |
| H-index | 30 | 38 |
| Hm-index | 14 | 16 |
| Number of Single Authored Papers | 12 | 12 |
| Total Cites to Single Authored Papers | 169 | 187 |
| Number of Single+First Authored Papers | 72 | 72 |
| Total Cites to Single+First Authored Papers | 1863 | 2387 |
| Number of Single+First+Last Authored Papers | 150 | 150 |
| Total Cites to Single+First+Last Authored Papers | 2956 | 3943 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 2550 | 2811 |
| Ratio of Total Citations to Distinct Citing Papers | 1.38 | 1.71 |
| Self-Citation Percentage |
26.89%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.